Skip to content
sellWeak cluster of 410b5-1 plan

Mark Elliott Boulding sold $1.6M of PTCT

EXEC. VP AND CLO at PTC THERAPEUTICS, INC.. 24,921 shares at an average of $65.75, traded Oct 3, 2025, filed Oct 7, 2025.

Warning score
25
Value
$1.6M
24,921 shares
Holdings after
103,901
-20% from before
From 52-week low
+87%
low $34.99, close $65.37
From 52-week high
0%
high $65.37, as of Oct 3, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $1.6M at market
    +25
  • Share of holdings sold
    Sold 20% of holdings
    +5
  • Cluster
    4 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +13.6%, 3m +20.0%, 6m +8.9%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

PTCTOct 13, 2026 · close 59.92
Since filing Oct 7, 2025: -6.2%SPY +17.5% · excess -23.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001578852-25-000005, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Oct 3, 2025MOption exercise
Common Stock10b5-1
+18,124$39.42$714k122,025Oct 7, 2025
Oct 3, 2025SOpen-market sale
Common Stock10b5-1
-3,100$64.43$200k118,925Oct 7, 2025
Oct 3, 2025SOpen-market sale
Common Stock10b5-1
-6,124$65.47$401k112,801Oct 7, 2025
Oct 3, 2025SOpen-market sale
Common Stock10b5-1
-7,400$66.44$492k105,401Oct 7, 2025
Oct 3, 2025SOpen-market sale
Common Stock10b5-1
-1,500$67.15$101k103,901Oct 7, 2025
Oct 3, 2025MOption exercise
Common Stock10b5-1
+2,266$39.42$89k106,167Oct 7, 2025
Oct 3, 2025SOpen-market sale
Common Stock10b5-1
-536$64.43$35k105,631Oct 7, 2025
Oct 3, 2025SOpen-market sale
Common Stock10b5-1
-824$65.73$54k104,807Oct 7, 2025
Oct 3, 2025SOpen-market sale
Common Stock10b5-1
-906$66.63$60k103,901Oct 7, 2025
Oct 3, 2025MOption exercise
Common Stock10b5-1
+2,265$39.42$89k106,166Oct 7, 2025
Oct 3, 2025SOpen-market sale
Common Stock10b5-1
-550$64.44$35k105,616Oct 7, 2025
Oct 3, 2025SOpen-market sale
Common Stock10b5-1
-838$65.72$55k104,778Oct 7, 2025
Oct 3, 2025SOpen-market sale
Common Stock10b5-1
-877$66.67$58k103,901Oct 7, 2025
Oct 6, 2025MOption exercise
Common Stock10b5-1
+2,266$39.42$89k106,167Oct 7, 2025
Oct 6, 2025SOpen-market sale
Common Stock10b5-1
-2,266$65.07$147k103,901Oct 7, 2025
Oct 3, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-18,124$0.00$018,126Oct 7, 2025
Oct 3, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-2,266$0.00$015,860Oct 7, 2025
Oct 3, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-2,265$0.00$013,595Oct 7, 2025
Oct 6, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-2,266$0.00$011,329Oct 7, 2025

Related signals

Other insiders at PTC THERAPEUTICS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
Pro nowfree Oct 20, 2026
PTCTsell 310b5-1
PTC THERAPEUTICS, INC.
Mark Elliott Boulding
EXEC. VP AND CLO
$12k
192 shares
-0%
Pro nowfree Oct 16, 2026
PTCTsell 310b5-1
PTC THERAPEUTICS, INC.
Michael Schmertzler
director
$158k
2,500 shares
-0%
6Weak
PTCTsell 310b5-1
PTC THERAPEUTICS, INC.
Mark Elliott Boulding
EXEC. VP AND CLO
$133k
2,073 shares
-2%
27Weak
PTCTsell 310b5-1
PTC THERAPEUTICS, INC.
Glenn Steele Jr Md Phd
director
$782k
12,000 shares
-35%
28Weak
PTCTsell 210b5-1
PTC THERAPEUTICS, INC.
Michael Schmertzler
director
$1.3M
20,000 shares
-2%
20Weak
PTCTsell10b5-1
PTC THERAPEUTICS, INC.
Michael Schmertzler
director
$1.4M
20,000 shares
-1%
28Weak
PTCTsell 210b5-1
PTC THERAPEUTICS, INC.
Michael Schmertzler
director
$1.8M
25,000 shares
-2%
28Weak
PTCTsell 210b5-1
PTC THERAPEUTICS, INC.
Michael Schmertzler
director
$1.8M
25,000 shares
-2%
7Weak
PTCTsell 310b5-1
PTC THERAPEUTICS, INC.
Mark Elliott Boulding
EXEC. VP AND CLO
$204k
2,813 shares
-3%
34Weak
PTCTsell 210b5-1
PTC THERAPEUTICS, INC.
Matthew B. Klein
CHIEF EXECUTIVE OFFICER
$706k
10,292 shares
-3%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Mark Elliott Boulding sold $1.6M of PTCT | InsiderTell